{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:15:53Z","timestamp":1788419753185,"version":"build-2803163510"},"reference-count":170,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Artificial intelligence (AI) is reshaping the dosing of medication. It is shifting practice from fixed schedules to flexible timing that better reflects the needs of individual patients. This review synthesizes recent work in which AI identifies improved windows for drug delivery. It spans multiple time horizons, ranging from minute-by-minute infusion control to regimen planning over weeks or months. These approaches integrate population pharmacokinetic modeling with machine learning and reinforcement learning. Each component serves a distinct purpose. Together, they can recommend the dose timing, adjust dosing intervals, and indicate when a planned treatment pause may be appropriate. The models link these recommendations to the physiological rhythms and current disease status of patients, so timing becomes a defined part of the dosing strategy rather than a simple clock-based rule. Recent advances cluster into three directions. First, reinforcement learning supports sequential dosing decisions in long-term therapies, where early choices shape later outcomes. Second, AI enables chronotherapy by aligning drug delivery with daily circadian biology. Third, hybrid models improve exposure prediction, which supports more accurate interval personalization for individual patients. However, key limitations remain. Many models show limited generalizability across clinical settings, and many methods still require rigorous clinical validation. Even with these constraints, the trajectory is consistent. AI is positioned to move therapeutic timing from a static calendar task to an adaptive, patient-centered element of precision medicine.<\/jats:p>","DOI":"10.3389\/fphar.2026.1890846","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:40:30Z","timestamp":1788417630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing"],"prefix":"10.3389","volume":"17","author":[{"given":"Yufeng","family":"Gong","sequence":"first","affiliation":[{"name":"Pharmacy Department, The First People\u2019s Hospital of Loudi","place":["Loudi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ren","sequence":"additional","affiliation":[{"name":"Pharmacy Department, The People\u2019s Hospital of Yuqing County","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Pharmacy Department, The First People\u2019s Hospital of Loudi","place":["Loudi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutian","family":"Wu","sequence":"additional","affiliation":[{"name":"Pharmacy Department, The First People\u2019s Hospital of Loudi","place":["Loudi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congyan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First People\u2019s Hospital of Loudi","place":["Loudi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e941","DOI":"10.1097\/CCM.0000000000006622","article-title":"Cystatin C-guided dosing nomogram improves target attainment for cefepime in the critically ill","volume":"53","author":"Barreto","year":"2025","journal-title":"Crit. Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/epi.18184","article-title":"Prediction of lacosamide concentrations to support dose optimization during pregnancy","volume":"66","author":"Barry","year":"2025","journal-title":"Epilepsia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41409-025-02742-8","article-title":"Usage of rabbit anti-thymocyte\/anti-T-lymphocyte globulins (ATG\/ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee","volume":"61","author":"Battipaglia","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/cpt.2511","article-title":"Machine learning application in a phase I clinical trial allows for the identification of clinical-biomolecular markers significantly associated with toxicity","volume":"111","author":"Bedon","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13054-025-05445-0","article-title":"First dose target attainment with extended infusion regimens of piperacillin and meropenem","volume":"29","author":"Beijer","year":"2025","journal-title":"Crit. Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/FTD.0000000000001217","article-title":"Simulation-based optimization of sampling schedules for model-informed precision dosing of once-daily and 4-times-daily busulfan in pediatric patients","volume":"46","author":"Ben Hassine","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"B7","doi-asserted-by":"publisher","first-page":"ofae171","DOI":"10.1093\/ofid\/ofae171","article-title":"Drug exposure of long-acting cabotegravir and rilpivirine in older people with human immunodeficiency virus: a pharmacokinetic modeling study","volume":"11","author":"Bettonte","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e00309","DOI":"10.1128\/aac.00309-23","article-title":"Cefepime population pharmacokinetics, antibacterial target attainment, and estimated probability of neurotoxicity in critically ill patients","volume":"67","author":"Bilal","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40262-024-01465-1","article-title":"Population pharmacokinetics of meropenem across the adult lifespan","volume":"64","author":"Boutzoukas","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"750672","DOI":"10.3389\/fphar.2021.750672","article-title":"Population pharmacokinetic model development of tacrolimus in pediatric and young adult patients undergoing hematopoietic cell transplantation","volume":"12","author":"Brooks","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jcph.1947","article-title":"Impact of obesity on brexpiprazole pharmacokinetics: proposal for improved initiation of treatment","volume":"62","author":"Bruno","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1287.e9","DOI":"10.1016\/j.cmi.2022.03.031","article-title":"Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy","volume":"28","author":"Butrague\u00f1o-Laiseca","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0172923","DOI":"10.1128\/aac.01729-23","article-title":"How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children","volume":"68","author":"Butrague\u00f1o-Laiseca","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11538-024-01375-0","article-title":"Steady-state drug exposure of repeated IV bolus administration for a one compartment pharmacokinetic model with sigmoidal hill elimination","volume":"86","author":"Cao","year":"2024","journal-title":"Bull. Math. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jcph.6126","article-title":"Physiologically based pharmacokinetic modeling of vancomycin and its comparison with population pharmacokinetic model in neonates","volume":"65","author":"Cao","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1002\/psp4.70152","article-title":"Pharmacokinetic model selection for personalized infliximab dosing in IBD","volume":"15","author":"Chaiben","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3390\/ani11072047","article-title":"Nonlinear mixed-effect pharmacokinetic modeling and distribution of doxycycline in healthy female donkeys after multiple intragastric dosing\u2013preliminary investigation","volume":"11","author":"Chapuis","year":"2021","journal-title":"Animals"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1093\/jac\/dkaf329","article-title":"Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients","volume":"80","author":"Chen","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cpt.3155","article-title":"Population pharmacokinetic analysis of atomoxetine and its metabolites in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"115","author":"Cheng","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/17425255.2025.2545918","article-title":"Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia","volume":"21","author":"Chepke","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e49643","DOI":"10.2196\/49643","article-title":"Data-driven identification of factors that influence the quality of adverse event reports: 15-year interpretable machine learning and time-series analyses of VigiBase and QUEST","volume":"12","author":"Choo","year":"2024","journal-title":"JMIR Med. Inf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/cts.12963","article-title":"A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors","volume":"14","author":"Chung","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"106751","DOI":"10.1016\/j.ijantimicag.2023.106751","article-title":"Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight","volume":"61","author":"Chung","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-024-00621-1","article-title":"The effect of polymorphisms and other biomarkers on infliximab exposure in paediatric inflammatory bowel disease: development of a population pharmacokinetic model","volume":"26","author":"Clemente-Bautista","year":"2024","journal-title":"Pediatr. Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11538-021-00976-3","article-title":"Designing drug regimens that mitigate nonadherence","volume":"84","author":"Counterman","year":"2022","journal-title":"Bull. Math. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s12325-024-02796-y","article-title":"Exposure\u2013response efficacy modeling to support trofinetide dosing in individuals with Rett syndrome","volume":"41","author":"Darwish","year":"2024","journal-title":"Adv. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/cpt.3176","article-title":"Reinforcement learning and PK-PD models integration to personalize the adaptive dosing protocol of erdafitinib in patients with metastatic urothelial carcinoma","volume":"115","author":"De Carlo","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/psp4.70012","article-title":"Precision dosing in presence of multiobjective therapies by integrating reinforcement learning and PK\u2013PD models: application to givinostat treatment of polycythemia vera","volume":"14","author":"De Carlo","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1288376","DOI":"10.3389\/fped.2023.1288376","article-title":"Pragmatic physiologically-based pharmacokinetic modeling to support clinical implementation of optimized gentamicin dosing in term neonates and infants: Proof-of-concept","volume":"11","author":"De Hoop-Sommen","year":"2023","journal-title":"Front. Pediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"10732748241264704","DOI":"10.1177\/10732748241264704","article-title":"Adaptive cancer therapy in the age of generative artificial intelligence","volume":"31","author":"Derbal","year":"2024","journal-title":"Cancer Control"},{"key":"B31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/FTD.0000000000001293","article-title":"Multiple model optimal sampling promotes accurate vancomycin area-under-the-curve estimation using a single sample in critically ill children","volume":"47","author":"Downes","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"B32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/FTD.0000000000000900","article-title":"Bayesian forecasting for intravenous tobramycin dosing in adults with cystic fibrosis using one versus two serum concentrations in a dosing interval","volume":"43","author":"Drennan","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1093\/jac\/dkae318","article-title":"Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?","volume":"79","author":"Duke","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/pharmaceutics14020408","article-title":"Ganciclovir pharmacokinetics and individualized dosing based on covariate in lung transplant recipients","volume":"14","author":"Dvo\u0159\u00e1\u010dkov\u00e1","year":"2022","journal-title":"Pharmaceutics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"17882","DOI":"10.1038\/s41598-021-97028-6","article-title":"Reinforcement learning derived chemotherapeutic schedules for robust patient-specific therapy","volume":"11","author":"Eastman","year":"2021","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1111\/bcp.15154","article-title":"Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations","volume":"88","author":"El Hassani","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1686415","DOI":"10.3389\/fphar.2025.1686415","article-title":"A digital twin of glimepiride for personalized and stratified diabetes treatment","volume":"16","author":"Elias","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/03007995.2025.2456014","article-title":"A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole","volume":"41","author":"Fagiolini","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2009.09051","article-title":"Deep reinforcement learning for closed-loop blood glucose control","author":"Fox","year":"2020","journal-title":"arXiv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17512433.2024.2304009","article-title":"Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study","volume":"17","author":"Fu","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s40262-021-01046-6","article-title":"Physiologically based pharmacokinetic modeling of meropenem in preterm and term infants","volume":"60","author":"Ganguly","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.therap.2025.09.002","article-title":"A new chapter in pharmacology: artificial intelligence\u2019s expanding role in pharmacokinetics, pharmacodynamics, and pharmacovigilance","volume":"81","author":"G\u00e9rard","year":"2025","journal-title":"Therapies"},{"key":"B43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/bcp.15177","article-title":"Concentration\u2013response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy","volume":"88","author":"Griesel","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/antibiotics14010048","article-title":"A quantitative examination and comparison of the ability of australian gentamicin dosing guidelines to achieve target therapeutic concentrations in neonates","volume":"14","author":"Grzeskowiak","year":"2025","journal-title":"Antibiotics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"107146","DOI":"10.1016\/j.ejps.2025.107146","article-title":"Applying exposure-response analysis to enhance mycophenolate mofetil dosing precision in pediatric patients with immune-mediated renal diseases by machine learning models","volume":"211","author":"Han","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.thromres.2023.10.009","article-title":"Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, a full-length recombinant factor VIII, in pediatric patients with haemophilia a","volume":"232","author":"He","year":"2023","journal-title":"Thromb. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e00741-22","DOI":"10.1128\/aac.00741-22","article-title":"Population pharmacokinetic modeling and probability of target attainment of ceftaroline in brain and soft tissues","volume":"66","author":"Helfer","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s12859-022-05117-8","article-title":"Prediction of vancomycin initial dosage using artificial intelligence models applying ensemble strategy","volume":"22","author":"Ho","year":"2023","journal-title":"BMC Bioinformatics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"10719","DOI":"10.1007\/s00210-025-03982-7","article-title":"Tacrolimus population pharmacokinetic model\u2013informed precision dosing in adult liver transplant patients","volume":"398","author":"Hou","year":"2025","journal-title":"Naunyn. Schmiedeb. Arch. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1005348","DOI":"10.3389\/fphar.2022.1005348","article-title":"External evaluation of published population pharmacokinetic models of posaconazole","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"386","DOI":"10.5414\/CP204793","article-title":"The vancomycin dosage calculator: prediction superiority and validation in a comparison of four algorithms using retrospective data from non-critical patients aged 18 to 59 years","volume":"63","author":"Huang","year":"2025","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40262-022-01185-4","article-title":"Evaluation of neonatal and paediatric vancomycin pharmacokinetic models and the impact of maturation and serum creatinine covariates in a large multicentre data set","volume":"62","author":"Hughes","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/FTD.0000000000001348","article-title":"Machine learning modeling for predicting infliximab pharmacokinetics in pediatric and young adult patients with crohn disease: leveraging ensemble modeling with synthetic and real-world data","volume":"48","author":"Irie","year":"","journal-title":"Ther. Drug Monit."},{"key":"B54","doi-asserted-by":"publisher","first-page":"70118","DOI":"10.1002\/cpt.70118","article-title":"Model-informed deep Q-networks to guide infliximab dosing in pediatric Crohn\u2019s disease","volume":"119","author":"Irie","year":"","journal-title":"Clin. Pharmacol. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40262-023-01305-8","article-title":"Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies","volume":"62","author":"Jansen","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"B56","doi-asserted-by":"publisher","first-page":"9415","DOI":"10.2147\/DDDT.S553644","article-title":"Renal function and hemoglobin independently predict levetiracetam exposure in epilepsy patients: a multifactorial regression study","volume":"19","author":"Jiang","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.3390\/curroncol29110685","article-title":"Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 TPS \u2265 50%: 3 weekly compared to 6 weekly dosing","volume":"29","author":"Jones","year":"2022","journal-title":"Curr. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e00962-23","DOI":"10.1128\/aac.00962-23","article-title":"Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study","volume":"67","author":"Kado","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/jcph.1986","article-title":"Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects","volume":"62","author":"Kawaguchi","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11523-024-01087-4","article-title":"An evidence-based rationale for dose de-escalation of subcutaneous atezolizumab","volume":"19","author":"Kicken","year":"2024","journal-title":"Target. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13063-025-08716-x","article-title":"A single-centre randomised controlled trial comparing the standard method and target-controlled infusion as a method of administering cefoxitin, which is used to prevent surgical site infections in colorectal surgical patients: study protocol","volume":"26","author":"Kim","year":"2025","journal-title":"Trials"},{"key":"B62","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s13318-022-00793-6","article-title":"Evaluating islatravir administered via microneedle array patch for long-acting HIV pre-exposure prophylaxis using physiologically based pharmacokinetic modelling","volume":"47","author":"Kinvig","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B63","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s13054-021-03863-4","article-title":"Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF)","volume":"25","author":"Kirwan","year":"2021","journal-title":"Crit. Care"},{"key":"B64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/JCP.0000000000001492","article-title":"Clozapine once-daily versus divided dosing regimen: a cross-sectional study in Japan","volume":"42","author":"Kitagawa","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2019.242289","article-title":"Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model","volume":"106","author":"Kloos","year":"2020","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.3324\/haematol.2023.283685","article-title":"Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: A population pharmacokinetic model","volume":"108","author":"Kloos","year":"2023","journal-title":"Haematologica"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/07420528.2025.2546008","article-title":"Multi-pulse chronotherapeutic approaches for circadian rhythm disease management","volume":"42","author":"Kole","year":"2025","journal-title":"Chronobiol. Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e70156","DOI":"10.1002\/psp4.70156","article-title":"A nonparametric population pharmacokinetic model of selumetinib in pediatric patients diagnosed with neurofibromatosis-I or plexiform neurofibromas","volume":"15","author":"K\u00f6ll\u0151","year":"2026","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jiac.2022.03.024","article-title":"Timing of re-dosing based on population pharmacokinetic-pharmacodynamics target attainment analysis of cefmetazole in subjects undergoing lower gastrointestinal surgery","volume":"28","author":"Komatsu","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jcyt.2024.01.004","article-title":"Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell\u2013depleted hematopoietic cell transplantation in pediatric and young adult patients","volume":"26","author":"Lakkaraja","year":"2024","journal-title":"Cytotherapy"},{"key":"B71","doi-asserted-by":"publisher","first-page":"39701","DOI":"10.1038\/s41598-025-23345-9","article-title":"Identifying medication use clusters with the R package tame based on dose, timing and ATC codes","volume":"15","author":"Laksafoss","year":"2025","journal-title":"Sci. Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.clinthera.2022.01.015","article-title":"Population pharmacokinetic and exposure\u2013response model simulations: predicted exposure and efficacy for maintenance doses of intravenous golimumab every 6 or 8 weeks in patients with moderately to severely active rheumatoid arthritis","volume":"44","author":"Lee","year":"2022","journal-title":"Clin. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e034862","DOI":"10.1161\/JAHA.124.034862","article-title":"Predicting individual treatment effects to determine duration of dual antiplatelet therapy after stent implantation","volume":"13","author":"Lee","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/jcph.70079","article-title":"Precision pharmacokinetics of quetiapine: a physiologically based model incorporating liver cirrhosis and CYP3A4 polymorphisms","volume":"65","author":"Lee","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"oyaf371","DOI":"10.1093\/oncolo\/oyaf371","article-title":"Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer","volume":"30","author":"LeVee","year":"2025","journal-title":"Oncologist"},{"key":"B76","doi-asserted-by":"publisher","first-page":"108044","DOI":"10.1016\/j.intimp.2021.108044","article-title":"Population pharmacokinetic simulation of varied immune globulin subcutaneous (human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-na\u00efve patients with primary immunodeficiency diseases","volume":"100","author":"Li","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/bcp.15572","article-title":"Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy","volume":"89","author":"Li","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1470350","DOI":"10.3389\/fphar.2024.1470350","article-title":"Population pharmacokinetics and dose optimization of ceftazidime in critically ill children","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.xphs.2024.03.002","article-title":"Physiologically-based pharmacokinetic modeling and dosing optimization of cefotaxime in preterm and term neonates","volume":"113","author":"Li","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"106915","DOI":"10.1016\/j.ejps.2024.106915","article-title":"Evaluation and application of population pharmacokinetic models for optimising linezolid treatment in non-adherence multidrug-resistant tuberculosis patients","volume":"203","author":"Li","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1478419","DOI":"10.3389\/fneur.2024.1478419","article-title":"Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy","volume":"15","author":"Li","year":"2024","journal-title":"Front. Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/antibiotics10040468","article-title":"Evaluation of the MeroRisk calculator, a user-friendly tool to predict the risk of meropenem target non-attainment in critically ill patients","volume":"10","author":"Liebchen","year":"2021","journal-title":"Antibiotics"},{"key":"B83","doi-asserted-by":"publisher","first-page":"bbac365","DOI":"10.1093\/bib\/bbac365","article-title":"A chronotherapeutics-applicable multi-target therapeutics based on AI: example of therapeutic hypothermia","volume":"23","author":"Liu","year":"2022","journal-title":"Brief. Bioinform."},{"key":"B84","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11095-023-03638-2","article-title":"PBPK\/PD modeling of nifedipine for precision medicine in pregnant women: enhancing clinical decision-making for optimal drug therapy","volume":"41","author":"Liu","year":"2024","journal-title":"Pharm. Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.2147\/DDDT.S493485","article-title":"Population pharmacokinetics of tranexamic acid in Chinese population undergoing cardiac surgery with cardiopulmonary bypass","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","article-title":"Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology","volume":"9","author":"Lu","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"27165","DOI":"10.1038\/s41598-024-78558-1","article-title":"Prediction of vancomycin plasma concentration in elderly patients based on multi-algorithm mining combined with population pharmacokinetics","volume":"14","author":"Ma","year":"","journal-title":"Sci. Rep."},{"key":"B88","doi-asserted-by":"publisher","first-page":"106876","DOI":"10.1016\/j.ejps.2024.106876","article-title":"Joint use of population pharmacokinetics and machine learning for prediction of valproic acid plasma concentration in elderly epileptic patients","volume":"201","author":"Ma","year":"","journal-title":"Eur. J. Pharm. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1093\/jac\/dkae292","article-title":"Prediction of teicoplanin plasma concentration in critically ill patients: a combination of machine learning and population pharmacokinetics","volume":"79","author":"Ma","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40263-022-00899-0","article-title":"Restoration of nusinersen levels following treatment interruption in people with spinal muscular atrophy: simulations based on a population pharmacokinetic model","volume":"36","author":"MacCannell","year":"2022","journal-title":"CNS Drugs"},{"key":"B91","doi-asserted-by":"publisher","first-page":"107884","DOI":"10.1016\/j.cmpb.2023.107884","article-title":"Deep reinforcement learning-based control of chemo-drug dose in cancer treatment","volume":"243","author":"Mashayekhi","year":"2024","journal-title":"Comput. Methods Programs Biomed."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s00228-022-03390-3","article-title":"Simulations of topiramate dosage recommendations for poor compliance events","volume":"78","author":"Methaneethorn","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/pharmaceutics16020253","article-title":"Population pharmacokinetic model of linezolid and probability of target attainment in patients with COVID-19-associated acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation\u2014a step toward correct dosing","volume":"16","author":"Milakovi\u0107","year":"2024","journal-title":"Pharmaceutics"},{"key":"B94","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/cancers17193262","article-title":"Optimizing anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring","volume":"17","author":"Monteiro","year":"2025","journal-title":"Cancers"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1109\/TBME.2020.3018464","article-title":"Imaging features of vessels and leakage patterns predict extended interval aflibercept dosing using ultra-widefield angiography in retinal vascular disease: findings from the PERMEATE study","volume":"68","author":"Moosavi","year":"2021","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"B96","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40262-025-01485-5","article-title":"Population pharmacokinetics of cefepime in critically ill children and young adults: model development and external validation for monte carlo simulations and model-informed precision dosing","volume":"64","author":"Morales Junior","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1111\/cas.16363","article-title":"Population pharmacokinetic model of ABL001\/CTX-009 (anti-VEGF\/DLL4) in adult cancer patients with solid tumor","volume":"115","author":"Na","year":"2024","journal-title":"Cancer Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/cpdd.1385","article-title":"Physiologically based pharmacokinetic absorption model for pexidartinib to evaluate the impact of meal contents and intake timing on drug exposure","volume":"13","author":"Nakayama","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/pan.15135","article-title":"Pentazocine pharmacodynamics in children: simulations to assess safety and effectiveness","volume":"35","author":"Omori","year":"2025","journal-title":"Pediatr. Anesth."},{"key":"B100","doi-asserted-by":"publisher","first-page":"znaf079","DOI":"10.1093\/bjs\/znaf079","article-title":"Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials","volume":"112","author":"Osawa","year":"2025","journal-title":"Br. J. Surg."},{"key":"B101","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13318-021-00709-w","article-title":"Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients: how to achieve best dosage regimen according to the clinical situation","volume":"46","author":"O\u2019Jeanson","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/jcph.1939","article-title":"Population pharmacokinetic modeling and simulations to evaluate a potential dose regimen of testosterone undecanoate in hypogonadal males","volume":"61","author":"Pastuszak","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7011376","article-title":"Discrepancies between bayesian vancomycin models can affect clinical decisions in the critically ill","volume":"2022","author":"Patanwala","year":"2022","journal-title":"Crit. Care Res. Pract."},{"key":"B104","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40120-025-00723-z","article-title":"Population pharmacokinetic modeling of TV-46000, a risperidone long-acting subcutaneous antipsychotic for the treatment of patients with schizophrenia","volume":"14","author":"Perlstein","year":"2025","journal-title":"Neurol. Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1111\/dom.15266","article-title":"Pharmacokinetic and pharmacodynamic properties of once\u2010weekly insulin icodec in individuals with type 2 diabetes","volume":"25","author":"Pieber","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"B106","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10103-025-04572-y","article-title":"A systematic review via text mining approaches of human and veterinary applications of photobiomodulation: focus on multiwave locked system laser therapy","volume":"40","author":"Previti","year":"2025","journal-title":"Lasers Med. Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"108919","DOI":"10.1016\/j.cmpb.2025.108919","article-title":"Pharmacometric and digital twin modeling for adaptive scheduling of combination therapy in advanced gastric cancer","volume":"270","author":"Prunella","year":"2025","journal-title":"Comput. Methods Programs Biomed."},{"key":"B108","doi-asserted-by":"publisher","first-page":"177777","DOI":"10.1016\/j.ejphar.2025.177777","article-title":"Toward precision dosing of linezolid in critical ill patients: efficiency and risk of thrombocytopenia analysis by population PKPD modeling and simulations","volume":"1002","author":"Qin","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/jcph.2303","article-title":"Predicted pharmacokinetic interactions between hormonal contraception and single or intermittently dosed rifampicin","volume":"63","author":"Radtke","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e01533-23","DOI":"10.1128\/aac.01533-23","article-title":"Opportunistic dried blood spot sampling validates and optimizes a pediatric population pharmacokinetic model of metronidazole","volume":"68","author":"Randell","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1007\/s11096-025-01998-w","article-title":"Population pharmacokinetics of imipenem and target attainment of pharmacokinetic\/pharmacodynamic indices in Chinese adults with febrile neutropenia and hematological malignancies","volume":"47","author":"Rao","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"B112","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1111\/bcp.15308","article-title":"Optimal dose of meropenem for the treatment of neonatal sepsis: dosing guideline variations and clinical practice deviations","volume":"88","author":"Raza","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e70223","DOI":"10.1111\/cts.70223","article-title":"Alternative dosing regimens of tislelizumab using a pharmacometrics model\u2010based approach","volume":"18","author":"Rizwan","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40262-025-01496-2","article-title":"Population pharmacokinetic modelling of remdesivir and its metabolite GS-441524 in hospitalised patients with COVID-19","volume":"64","author":"Roberts","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e03030","DOI":"10.1002\/adhm.202503030","article-title":"Transdermal drug delivery systems powered by artificial intelligence","volume":"14","author":"Sabbagh","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.23.25338698","article-title":"Personalized hemodynamic management using reinforcement learning to prevent persistent acute kidney injury after cardiac surgery","author":"Sabounchi","year":"2025"},{"key":"B117","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s10916-025-02187-y","article-title":"Target-controlled infusion of propofol: a systematic review of recent results","volume":"49","author":"\u0160afr\u00e1nkov\u00e1","year":"2025","journal-title":"J. Med. Syst."},{"key":"B118","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1080\/15563650.2021.1896731","article-title":"Population pharmacokinetics of pseudechis porphyriacus (red-bellied black snake) venom in snakebite patients","volume":"59","author":"Sanhajariya","year":"2021","journal-title":"Clin. Toxicol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/17425255.2023.2250251","article-title":"Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs","volume":"19","author":"Schagen","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40262-025-01486-4","article-title":"Leveraging clinical data to enhance the performance evaluation of ceftriaxone population pharmacokinetic models in children","volume":"64","author":"Schouwenburg","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B120","doi-asserted-by":"publisher","first-page":"8930","DOI":"10.1038\/s41598-022-12627-1","article-title":"Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients","volume":"12","author":"Setiawan","year":"2022","journal-title":"Sci. Rep."},{"key":"B121","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40262-021-01093-z","article-title":"Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: towards individualized dosing regimens","volume":"61","author":"Shah","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"B122","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/antibiotics12040643","article-title":"Population pharmacokinetic study of benzylpenicillin in critically unwell adults","volume":"12","author":"Shah","year":"2023","journal-title":"Antibiotics"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.jtha.2024.04.005","article-title":"A deep-learning approach to predict bleeding risk over time in patients on extended anticoagulation therapy","volume":"22","author":"Shahryari Fard","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B124","doi-asserted-by":"publisher","first-page":"916253","DOI":"10.3389\/fphar.2022.916253","article-title":"Optimal dose of cefotaxime in neonates with early-onset sepsis: a developmental pharmacokinetic model-based evaluation","volume":"13","author":"Shang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1013432","DOI":"10.3389\/fphar.2022.1013432","article-title":"Predictive performance and verification of physiologically based pharmacokinetic model of propylthiouracil","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1671652","DOI":"10.3389\/fphar.2025.1671652","article-title":"Precision dosing of voriconazole in immunocompromised children under 2 years: integrated machine learning and population pharmacokinetic modeling","volume":"16","author":"Shen","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1525991","DOI":"10.3389\/fmicb.2025.1525991","article-title":"Changes in the blood cyclosporine level after switching from voriconazole to isavuconazole in a patient with aplastic anemia: insights from physiologically based pharmacokinetic model simulation and the adverse event reporting system database study","volume":"16","author":"Shiraishi","year":"2025","journal-title":"Front. Microbiol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13550-023-01008-y","article-title":"Predicting the effect of different folate doses on [68Ga]ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling","volume":"13","author":"Siebinga","year":"2023","journal-title":"EJNMMI Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/jcph.70101","article-title":"Population pharmacokinetics and dose simulation of levetiracetam in patients with epilepsy: influence of renal function and phenytoin co\u2010administration","volume":"65","author":"Singkham","year":"2025","journal-title":"J. Clin. Pharmacol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000526210","article-title":"Oral ibuprofen is more effective than intravenous ibuprofen for closure of a patent ductus arteriosus: can pharmacokinetic modeling help us to understand why?","volume":"120","author":"Smit","year":"2023","journal-title":"Neonatology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/17512433.2025.2594496","article-title":"Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations","volume":"18","author":"Snoeck","year":"2025","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s13318-021-00695-z","article-title":"Population pharmacokinetics and dose optimization of vancomycin in critically ill children","volume":"46","author":"Sridharan","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B132","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1111\/epi.18517","article-title":"Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model","volume":"66","author":"Stoschus","year":"2025","journal-title":"Epilepsia"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/bcp.14578","article-title":"Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study","volume":"87","author":"Tang","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40262-023-01265-z","article-title":"Use of machine learning for dosage individualization of vancomycin in neonates","volume":"62","author":"Tang","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40262-024-01400-4","article-title":"Machine learning approach in dosage individualization of isoniazid for tuberculosis","volume":"63","author":"Tang","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"B136","doi-asserted-by":"publisher","first-page":"e01427-21","DOI":"10.1128\/AAC.01427-21","article-title":"Population pharmacokinetic modeling of total and free ceftriaxone in critically ill children and young adults and monte carlo simulations support twice daily dosing for target attainment","volume":"66","author":"Tang Girdwood","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B137","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bcp.14436","article-title":"Model informed dosing of hydroxycholoroquine in COVID\u201019 patients: learnings from the recent experience, remaining uncertainties and gaps","volume":"87","author":"Th\u00e9mans","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jid.2025.01.031","article-title":"Personalizing biologic therapy in psoriasis: development, validation, and user testing of a precision-dosing dashboard","volume":"145","author":"Thomas","year":"2025","journal-title":"J. Invest. Dermatol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","article-title":"Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia a: a population pharmacokinetic model","volume":"106","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"B140","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10928-023-09874-8","article-title":"Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease","volume":"50","author":"Tiraboschi","year":"2023","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1904.01200","article-title":"Personalized cancer chemotherapy schedule: a numerical comparison of performance and robustness in model-based and model-free scheduling methodologies","author":"Tordesillas","year":"2019","journal-title":"arXiv"},{"key":"B142","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/cpt.3356","article-title":"Model-informed reinforcement learning for enabling precision dosing Via adaptive dosing","volume":"116","author":"Tosca","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B143","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/medsci13040235","article-title":"Optimizing mycophenolate therapy in renal transplant patients using machine learning and population pharmacokinetic modeling","volume":"13","author":"Tsyplakova","year":"2025","journal-title":"Med. Sci."},{"key":"B144","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s13318-024-00900-9","article-title":"Model-informed clinical development of once-every-6-month injection of paliperidone palmitate in patients with schizophrenia: a pharmacometric bridging approach (part I)","volume":"49","author":"T\u2019jollyn","year":"","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B145","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s13318-024-00899-z","article-title":"Model-informed clinical development of 6-monthly injection of paliperidone palmitate in patients with schizophrenia: dosing strategies guided by population pharmacokinetic modeling and simulation (part II)","volume":"49","author":"T\u2019jollyn","year":"","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/psp4.70014","article-title":"Pharmacokinetic model-informed precision dosing of natalizumab in multiple sclerosis","volume":"14","author":"Van Den Berg","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1416440","DOI":"10.3389\/fped.2024.1416440","article-title":"Getting the dose right using physiologically-based pharmacokinetic modeling: dexamethasone to prevent post-extubation stridor in children as proof of concept","volume":"12","author":"Van Der Heijden","year":"2024","journal-title":"Front. Pediatr."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e01118-24","DOI":"10.1128\/aac.01118-24","article-title":"Amikacin dosing in neonates: evaluation of target attainment using a simplified and complex pharmacokinetic model-derived dosing regimen in clinical practice","volume":"69","author":"Van Der Veer","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B149","doi-asserted-by":"publisher","first-page":"e70077","DOI":"10.1111\/cts.70077","article-title":"Integrating real-world data and machine learning: a framework to assess covariate importance in real-world use of alternative intravenous dosing regimens for atezolizumab","volume":"17","author":"Vora","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B150","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cpdd.1397","article-title":"Population pharmacokinetics and dosing simulations for aripiprazole 2-month ready-to-use long-acting injectable in adult patients with schizophrenia or bipolar I disorder","volume":"13","author":"Wang","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B151","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/cpdd.1580","article-title":"Exposure\u2013response analysis for aripiprazole once-monthly in patients diagnosed with bipolar I disorder","volume":"14","author":"Wang","year":"2025","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B152","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jvp.13506","article-title":"Pharmacokinetics of ampicillin-sulbactam in azotemic and non-azotemic dogs","volume":"48","author":"Wang","year":"2025","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"B153","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1213\/ANE.0000000000005527","article-title":"Prediction of prolonged opioid use after surgery in adolescents: insights from machine learning","volume":"133","author":"Ward","year":"2021","journal-title":"Anesth. Analg."},{"key":"B154","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/bjd\/ljae439","article-title":"Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis","volume":"192","author":"Weidinger","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cpt.2123","article-title":"Tacrolimus exposure prediction using machine learning","volume":"110","author":"Woillard","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B156","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11096-023-01657-y","article-title":"Managing delayed or missed pregabalin doses in patients with focal epilepsy: a monte carlo simulation study","volume":"46","author":"Xie","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B157","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdd.2325","article-title":"Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling","volume":"43","author":"Xu","year":"2022","journal-title":"Biopharm. Drug Dispos."},{"key":"B158","doi-asserted-by":"publisher","first-page":"111914","DOI":"10.1016\/j.jtbi.2024.111914","article-title":"Optimal STI controls for HIV patients based on an efficient deep Q learning method","volume":"594","author":"Yoon","year":"2024","journal-title":"J. Theor. Biol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/ai6050087","article-title":"Deep reinforcement learning for automated insulin delivery systems: algorithms, applications, and prospects","volume":"6","author":"Yu","year":"2025","journal-title":"AI"},{"key":"B160","doi-asserted-by":"publisher","first-page":"499","DOI":"10.17219\/acem\/145947","article-title":"Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (humira\u00ae) in healthy subjects and ankylosing spondylitis patients: population pharmacokinetic modeling","volume":"31","author":"Zeng","year":"2022","journal-title":"Adv. Clin. Exp. Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1439232","DOI":"10.3389\/fphar.2024.1439232","article-title":"Individualized dosing parameters for tacrolimus in the presence of voriconazole: a real-world PopPK study","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"e02274-24","DOI":"10.1128\/spectrum.02274-24","article-title":"Population pharmacokinetics of vancomycin in non-extremely preterm neonates based on real-world studies: influence of daily fluid input and diuretics","volume":"13","author":"Zhao","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e0317662","DOI":"10.1371\/journal.pone.0317662","article-title":"A safe-enhanced fully closed-loop artificial pancreas controller based on deep reinforcement learning","volume":"20","author":"Zhao","year":"2025","journal-title":"PLoS One"},{"key":"B164","doi-asserted-by":"publisher","first-page":"106697","DOI":"10.1016\/j.ejps.2024.106697","article-title":"Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy","volume":"194","author":"Zheng","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"B165","doi-asserted-by":"publisher","first-page":"622","DOI":"10.2174\/0113892002348045241210071452","article-title":"Characterizing pharmacokinetic variability of topiroxostat in Chinese population: insights from a phase I randomized clinical trial","volume":"25","author":"Zhong","year":"2025","journal-title":"Curr. Drug Metab."},{"key":"B166","doi-asserted-by":"publisher","first-page":"146","DOI":"10.21037\/jgo-2024-963","article-title":"Liver microsomal protein content and activity in patients with hepatocellular carcinoma and cirrhosis: implications for the in vivo prediction of individual hepatic clearance","volume":"16","author":"Zhou","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"107301","DOI":"10.1016\/j.ejps.2025.107301","article-title":"Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants","volume":"215","author":"Zhou","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/bcp.15608","article-title":"Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation","volume":"89","author":"Zwart","year":"2023","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1890846\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:40:32Z","timestamp":1788417632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1890846\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":170,"alternative-id":["10.3389\/fphar.2026.1890846"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1890846","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1890846"}}